Institutional members access full text with Ovid®

Share this article on:

Delayed Topical p38 MAPK Inhibition Attenuates Full-Thickness Burn Wound Inflammatory Signaling

Carter, Damien MD; Warsen, Adelaide MS; Mandell, Katherine MD; Cuschieri, Joseph MD; Maier, Ronald V. MD; Arbabi, Saman MD, MPH

doi: 10.1097/BCR.0b013e31828a8d6e
Original Articles

Inflammatory signaling pathways, such as p38 mitogen-activated protein kinase (MAPK) play a central role in host responses to injury. In previous studies by the authors, topical p38 MAPK inhibitors effectively attenuated inflammatory signaling in a partial-thickness scald burn model, when applied to the burn wound immediately after injury. However, clinically relevant full-thickness scald burn wounds may act as a barrier to topical immune modulators, and delayed application of topical p38 MAPK inhibitors may not be effective. In this study, the authors evaluate the efficacy of topical p38 MAPK inhibition on full-thickness scald burns with immediate and delayed treatment. C57/BL6 mice received “Sham” or 30% TBSA full-thickness scald burn injury. After injury, the burn wounds were treated with a topical p38 MAPK inhibitor or vehicle. The treatment group received topical p38 MAPK inhibitor either immediately after burn or 4 hours (delayed) after injury. All animals were killed at 12 or 24 hours. Burn wounds underwent histological analyses. Skin and plasma were analyzed by enzyme-linked immunosorbent assay or real-time quantitative polymerase chain reaction for cytokine expression. Full-thickness scald burns resulted from immersion in 62°C water for 25 seconds. Topical p38 MAPK inhibitor attenuated dermal interleukin (IL)-6, MIP-2, and IL-1β expression and plasma IL-6 and MIP-2 cytokine expression. In addition, delayed application of topical p38 MAPK inhibitors significantly reduced dermal and plasma cytokine expression compared with vehicle control. Topical p38 MAPK inhibitors remain potent in reducing full-thickness burn wound inflammatory signaling, even when treatment is delayed by several hours postinjury. Topical application of p38 MAPK inhibitor may be a clinically viable treatment after burn injury.

From Department of Surgery, Harborview Medical Center, University of Washington, Seattle.

This work was supported by NIH GM084132-01 (PI: Arbabi).

Dr Arbabi has received a grant from Array BioPharma Inc. to study postburn application of Arry-797 in a pig model of wound healing.

Address correspondence to Saman Arbabi, MD, MPH, FACS, Professor of Surgery, University of Washington, Harborview Medical Center, Box 359796, 325 9th Ave, Seattle, Washington 98104.

© 2014 The American Burn Association